• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cyber attack stalls manufacturing for Merck, narrows outlook

July 28, 2017 By Sarah Faulkner

MerckMerck (NYSE:MRK) narrowed its full-year earnings outlook while announcing its second quarter results today. The company revealed that an international cyber attack, which hit the drugmaker in June, halted some of its manufacturing operations.

While touting its second quarter financial results, Merck said that it doesn’t yet fully comprehend the magnitude of the disruption caused by the cyber attack and that it is still restoring its operations.

“Full recovery from the cyber-attack will take some time, but we are making steady progress,” CEO Ken Frazier said on the company’s conference call, according to Reuters.

On its earnings call, the company said that its full-year EPS forecast would have been higher if not for the cyberattack.

The company reported that there will likely be temporary delays on orders for a few of its drugs, but not for key products like its cancer drug, Keytruda.

Merck’s net income rose 61% to $1.95 billion, or 71¢ per share, in the three months ending June 30, compared to the same period last year. Sales for the quarter rose 1% to $9.93 billion, easily beating analysts’ estimates of $9.75 billion.

Adjusted to exclude one-time items, earnings per share were $1.01, ahead of consensus on The Street, where analysts expected 87¢.

Material from Reuters was used in this report.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Merck

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS